| Time course of degenerative alterations in nigral dopaminergic neurons following a 6‐hydroxydopamine lesion CL Zuch, VK Nordstroem, LA Briedrick, GR Hoernig, AC Granholm, ... Journal of Comparative Neurology 427 (3), 440-454, 2000 | 192 | 2000 |
| Targeting multiple myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell–recruiting antibody optimized for cytotoxicity and cytokine release CLZ de Zafra, F Fajardo, W Zhong, MJ Bernett, US Muchhal, GL Moore, ... Clinical Cancer Research 25 (13), 3921-3933, 2019 | 109 | 2019 |
| Low-level lead exposure selectively enhances dopamine overflow in nucleus accumbens: AnIn VivoElectrochemistry time course assessment CL Zuch, DJ O'Mara, DA Cory-Slechta Toxicology and applied pharmacology 150 (1), 174-185, 1998 | 92 | 1998 |
| Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody K Staflin, CLZ de Zafra, LK Schutt, V Clark, F Zhong, M Hristopoulos, ... JCI insight 5 (7), 2020 | 75 | 2020 |
| Host cell proteins in biotechnology‐derived products: A risk assessment framework CLZ de Zafra, V Quarmby, K Francissen, M Vanderlaan, J Zhu‐Shimoni Biotechnology and bioengineering 112 (11), 2284-2291, 2015 | 49 | 2015 |
| Mitigation of oxidation in therapeutic antibody formulations: A biochemical efficacy and safety evaluation of N-acetyl-tryptophan and L-methionine MZ Dion, D Leiske, VK Sharma, CLZ de Zafra, CM Salisbury Pharmaceutical research 35 (11), 1-11, 2018 | 31 | 2018 |
| Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics CLZ de Zafra, VG Sasseville, S Matsumoto, C Freichel, M Milton, ... Regulatory Toxicology and Pharmacology 86, 221-230, 2017 | 27 | 2017 |
| Balancing efficacy and safety of an anti-DLL4 antibody through pharmacokinetic modulation JA Couch, G Zhang, JC Beyer, CLZ de Zafra, P Gupta, AV Kamath, ... Clinical Cancer Research 22 (6), 1469-1479, 2016 | 25 | 2016 |
| Comparison of the stimulus properties of a pre-vs. a putative postsynaptic dose of quinpirole DA Cory-Slechta, CL Zuch, RAV Fox Pharmacology Biochemistry and Behavior 55 (3), 423-432, 1996 | 24 | 1996 |
| Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey CLZ De Zafra, A Ashkenazi, WC Darbonne, M Cheu, K Totpal, S Ortega, ... Cell death & disease 7 (8), e2338-e2338, 2016 | 22 | 2016 |
| Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys L Xu, CL Zuch, YS Lin, NB Modi, BL Lum Cancer chemotherapy and pharmacology 61 (4), 607-614, 2008 | 21 | 2008 |
| Overview of biopharmaceuticals and comparison with small-molecule drug development T Reynolds, C de Zafra, A Kim, TR Gelzleichter Nonclinical development of novel biologics, biosimilars, vaccines and …, 2013 | 20 | 2013 |
| Beneficial effects of intraventricularly administered BMP-7 following a striatal 6-hydroxydopamine lesion CL Zuch, D David, L Ujhelyi, JL Hudson, GA Gerhardt, PL Kaplan, ... Brain research 1010 (1-2), 10-16, 2004 | 19 | 2004 |
| Preclinical characterization of AMG 424, a novel humanized T cell-recruiting bispecific anti-CD3/CD38 antibody C de Zafra, M Balazs, F Fajardo, L Liang, W Zhong, A Henn, MJ Bernett, ... Blood 130 (Supplement 1), 500-500, 2017 | 17 | 2017 |
| Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: nonclinical safety and pharmacokinetics J Gaudreault, V Shiu, A Bricarello, BJ Christian, CL Zuch, B Mounho International journal of toxicology 24 (5), 357-363, 2005 | 16 | 2005 |
| Rapid development of glaucoma via ITV nonselective ANGPT 1/2 antibody: a potential role for ANGPT/TIE2 signaling in primate aqueous humor outflow EA Thackaberry, Y Zhou, CLZ de Zafra, G Fuh, CV Lee, S Sanowar, ... Investigative ophthalmology & visual science 60 (13), 4097-4108, 2019 | 11 | 2019 |
| Stimulus properties of 7-OH-DPAT versus auto-and postsynaptic receptor-specific doses of quinpirole CL Zuch, DA Cory-Slechta Pharmacology Biochemistry and Behavior 68 (3), 469-479, 2001 | 11 | 2001 |
| Abuse liability assessment for biologic drugs–All molecules are not created equal CLZ de Zafra, CG Markgraf, DR Compton, TJ Hudzik Regulatory Toxicology and Pharmacology 92, 165-172, 2018 | 5 | 2018 |
| 783 SGN-PDL1V, a novel, investigational PD-L1-directed antibody-drug conjugate for the treatment of solid tumors B Kwan, M Ramirez, S Jin, C Yu, S Wo, P Gupta, S Allred, J Simmons, ... Journal for Immunotherapy of Cancer 9 (Suppl 2), A818-A818, 2021 | 1 | 2021 |
| Repeat-dose intravitreal administration of a humanized monoclonal antibody is poorly tolerated in rabbits CZ de Zafra, C Farman, E Wakshull, CV Pastuskovas, L Geiger, PE Miller, ... Investigative Ophthalmology & Visual Science 56 (7), 3640-3640, 2015 | 1 | 2015 |
